These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22895288)

  • 1. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 3. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 8. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of accuracy in HER2 testing.
    Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):529-31. PubMed ID: 23073051
    [No Abstract]   [Full Text] [Related]  

  • 13. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 17. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India.
    Ghosh J; Gupta S; Desai S; Shet T; Radhakrishnan S; Suryavanshi P; Parmar V; Jalali R; Goyal G; Hawaldar R; Patil A; Nair N; Badwe RA
    Indian J Cancer; 2011; 48(4):391-6. PubMed ID: 22293249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.